New Hampshire Trust Lowers Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

New Hampshire Trust trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,513 shares of the company’s stock after selling 30 shares during the period. New Hampshire Trust’s holdings in IDEXX Laboratories were worth $2,693,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the business. Mercer Global Advisors Inc. ADV lifted its holdings in IDEXX Laboratories by 4.3% in the second quarter. Mercer Global Advisors Inc. ADV now owns 4,295 shares of the company’s stock valued at $2,039,000 after acquiring an additional 176 shares during the period. Benjamin F. Edwards & Company Inc. increased its holdings in shares of IDEXX Laboratories by 2.8% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,657 shares of the company’s stock valued at $807,000 after purchasing an additional 45 shares in the last quarter. Bridges Investment Management Inc. purchased a new position in shares of IDEXX Laboratories in the 2nd quarter valued at about $255,000. AE Wealth Management LLC lifted its stake in shares of IDEXX Laboratories by 16.6% in the second quarter. AE Wealth Management LLC now owns 7,957 shares of the company’s stock valued at $3,877,000 after purchasing an additional 1,134 shares during the period. Finally, Pacer Advisors Inc. boosted its holdings in IDEXX Laboratories by 25.2% during the second quarter. Pacer Advisors Inc. now owns 12,013 shares of the company’s stock worth $5,853,000 after buying an additional 2,416 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of research analyst reports. Leerink Partners started coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Finally, Barclays cut their price target on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average target price of $523.86.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now directly owns 905 shares of the company’s stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.18% of the stock is owned by company insiders.

IDEXX Laboratories Stock Down 2.2 %

Shares of NASDAQ:IDXX opened at $419.26 on Tuesday. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $34.33 billion, a P/E ratio of 40.43, a P/E/G ratio of 3.53 and a beta of 1.36. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39. The stock’s fifty day simple moving average is $423.60 and its 200-day simple moving average is $457.86.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. During the same period in the prior year, the firm earned $2.53 EPS. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.